Granulocyte Colony-Stimulating Factor (GCSF) Use with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone plus /- Rituximab ( CHOP±R) Treatment for Aggressive Non-Hodgkin's Lymphoma (aNHL)

被引：0
|
作者：
Kouroukis, Tom [1 ]
Cheung, Winson Y. [2 ]
Abdel-Samad, Nizar [3 ]
Sehdev, Sandeep [4 ]
Poulin-Costello, Melanie [5 ]
Gillesby, Brad [5 ]
Robson, Ewan J. D. [5 ]
机构：
[1] Juravinski Canc Ctr, Hamilton, ON, Canada
[2] British Columbia Canc Agcy, Vancouver, BC, Canada
[3] Moncton Hosp, Moncton, NB, Canada
[4] William Osler Hlth Syst, Brampton, ON, Canada
[5] Amgen Canada Inc, Mississauga, ON, Canada
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3038.3038
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3038
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients:: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor
    Hernandez, D. E.
    Hernandez, A. E.
    EUROPEAN JOURNAL OF CANCER CARE, 2006, 15 (05) : 493 - 496
  • [22] Cost-Benefit Analysis of Prophylactic Granulocyte Colony-Stimulating Factor During CHOP Antineoplastic Therapy for Non-Hodgkin’s Lymphoma
    George Dranitsaris
    Christopher Altmayer
    Ian Quirt
    PharmacoEconomics, 1997, 11 : 566 - 577
  • [23] Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide,vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma
    Tulpule, Anil
    Espina, Byron M.
    Berman, Nancy
    Buchanan, Laura H.
    Smith, D. Lynne
    Sherrod, Andy
    Dharmapala, Dharshika
    Gee, Conway
    Boswell, William D.
    Nathwani, Bharat N.
    Welles, Lauri
    Levine, Alexandra M.
    CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (01): : 59 - 64
  • [24] Use of Granulocyte Colony-Stimulating Factor and Neutropenic Events among Breast Cancer and Non-Hodgkin's Lymphoma Patients
    Lin, Wan-Ting
    Wen, Tsun-Jen
    Chiang, Shao-Chin
    Shen, Li-Jiuan
    Hsiao, Fei-Yuan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 243 - 244
  • [25] Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment of primary gastrointestinal B-cell lymphoma
    Aguiar Bujanda, D.
    Cabrera Suarez, M. A.
    Llorca Martinez, I.
    Bohn Sarmiento, U.
    Saura Grau, S.
    Rodriguez Franco, C.
    Aguiar Morales, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] Efficacy of fludarabine, mitoxantrone, dexamethasone alternating with cyclophosphamide, doxorubicin, vincristine and prednisone (FMD/CHOP) in bulky follicular non-Hodgkin's lymphoma
    Wilder, DD
    Ogden, JL
    Jain, VK
    BLOOD, 2001, 98 (11) : 603A - 603A
  • [27] Successful treatment of diffuse large B-cell non-Hodgkin lymphoma with modified CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy and rituximab in a patient with Nijmegen syndrome
    Dumic, Miroslav
    Radman, Ivo
    Krnic, Nevena
    Nola, Marin
    Kusec, Rajko
    Begovic, Davor
    Labar, Boris
    Rados, Marko
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (09): : 590 - 593
  • [28] Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor:: Identification of two age subgroups with differing hematologic toxicity
    Gómez, H
    Mas, L
    Casanova, L
    Pen, DLK
    Santillana, S
    Valdivia, S
    Otero, J
    Rodriguez, W
    Carracedo, C
    Vallejos, C
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) : 2352 - 2358
  • [29] An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study
    Flinn, Ian W.
    Van der Jagt, Richard H.
    Kahl, Brad S.
    Wood, Peter
    Hawkins, Tim E.
    MacDonald, David
    Hertzberg, Mark
    Kwan, Yiu-Lam
    Simpson, David
    Craig, Michael
    Kolibaba, Kathryn
    Issa, Samar
    Munteanu, Mihaela C.
    Clementi, Regina
    Chen, Ling
    Burke, John M.
    BLOOD, 2012, 120 (21)
  • [30] Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis
    Linschoten, Marijke
    Kamphuis, Janine A. M.
    Van Rhenen, Anna
    Bosman, Laurens P.
    Cramer, Maarten J.
    Doevendans, Pieter A.
    Teske, Arco J.
    Asselbergs, Folkert W.
    LANCET HAEMATOLOGY, 2020, 7 (04): : E295 - E308
12345